Despite programmed cell death protein 1/ligand 1 (PD-1/PD-L1) blockade significantly improving the survival of patients with advanced lung cancer, a certain number of patients fail to respond to PD-1/PD-L1 blockade therapy, or eventually progress after an initial response [2,3]. This evidence concerns the gene CD274 and lung cancer.